HPV vaccines and cancer prevention, science versus activism vaccines and cancer prevention, science versus activism

Infectious Agents and Cancer

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

HPV vaccines and cancer prevention, science versus activism

Infectious Agents and Cancer 2013, 8:6 doi:10.1186/1750-9378-8-6

Lucija Tomljenovic (lucijat77@gmail.com) Judy Wilyman (rjw915@uowmail.edu.au) Eva Vanamee (eva.vanamee@mssm.edu) Toni Bark (tonibark@me.com) Christopher A Shaw (cashawlab@gmail.com)

ISSN Article type Submission date Acceptance date Publication date Article URL

1750-9378 Letter to the Editor 9 January 2013 21 January 2013 1 February 2013 http://www.infectagentscancer.com/content/8/1/6

This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in Infectious Agents and Cancer are listed in PubMed and archived at PubMed Central. For information about publishing your research in Infectious Agents and Cancer or any BioMed

Central journal, go to


For information about other BioMed Central publications go to


© 2013 Tomljenovic et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HPV vaccines and cancer prevention, science versus activism

Lucija Tomljenovic1* * Corresponding author Email: lucijat77@gmail.com

Judy Wilyman2 Email: rjw915@uowmail.edu.au

Eva Vanamee3 Email: eva.vanamee@mssm.edu

Toni Bark4 Email: tonibark@me.com

Christopher A Shaw1 Email: cashawlab@gmail.com

1 Neural Dynamics Research Group, Vancouver General Hospital Research Pavilion, University of British Columbia, 828 W. 10th Ave, Vancouver, BC V5Z 1L8, Canada

2 School of Social Sciences, Media and Communication, University of Wollongong, Wollongong 2522, Australia

3 Department of Structural and Chemical Biology, Mount Sinai School of Medicine, 1425 Madison Ave., Rm 1623, New York, NY 10029, USA

4 School of Public Health-Healthcare Emergency Management, Boston University, Boston, MA 02118, USA


The rationale behind current worldwide human papilloma virus (HPV) vaccination programs starts from two basic premises, 1) that HPV vaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side effects. Therefore, efforts should be made to get as many pre-adolescent girls vaccinated in order to decrease the burden of cervical cancer. Careful analysis of HPV vaccine pre- and post-licensure data shows however that both of these premises are at odds with factual evidence and are largely derived from significant misinterpretation of available data.


The recent Editorial by Silvia de Sanjosé* [1] is problematic from a variety of perspectives. Mainly, it attempts to portray a complex issue as a simple dichotomy between supposedly

unjustified “anti-HPV vaccine activism” and alleged absolute science which has presumably provided indisputable evidence on HPV vaccine safety and efficacy.

In spite of much unwarranted and premature optimism, the fact is however that HPV vaccines have not thus far prevented a single case of cervical cancer (let alone cervical cancer death). Instead, what the clinical trials have shown is that HPV vaccines can prevent some of the pre- cancerous CIN 2/3 lesions associated with HPV-16 and HPV-18 infection, a large fraction of which would spontaneously resolve regardless of the vaccination status [2-4]. For example, in adolescent women aged 13 to 24 years, 38% of CIN 2 resolve after one year, 63% after two and 68% after three years [5]. Moreover, the validity of CIN 2 being a cancer precursor is questionable due to high misclassification rates and poor intra- and inter-observer reproducibility in diagnosis, as well as high regression rates [6-9]. According to Castle et al. [7] CIN 2 is the least reproducible of all histopathologic diagnoses and may in part reflect sampling error. While CIN 3 is a more reliable marker for cancer progression than CIN 2, the use of this marker is not without caveats [2,10].

Indeed, the optimistic assumption that HPV vaccination (even if proven effective against cervical cancer as claimed), will result in 70% reduction of cervical cancers appears to be largely based on premature, exaggerated and invalid surrogate marker-based extrapolations [2,11]. Crucially, these assumptions failed to take into account several important real-world factors such as:

(1) reliability of surrogate-markers (i.e., whether they can accurately measure what they are purport to measure);

(2) efficacy against oncogenic HPV strains not covered by the vaccine; (3) possibility of increased frequency of infections with these types; (4) efficacy in women acquiring multiple HPV types; (5) effects in women with pre-existing HPV infections

It is also noteworthy that Merck’s HPV vaccine Gardasil received priority Fast Track approval by the U.S. Food and Drug Administration (FDA) after a 6-month review process, despite the fact that it failed (and still continues to fail) to meet a single one of the four criteria required by the FDA for Fast Track approval. Gardasil is demonstrably neither safer nor more effective than Pap screening combined with the loop electrosurgical excision procedure (LEEP) in preventing cervical cancers, nor can it improve the diagnosis of serious cervical cancer outcomes [12]. In this regard, Gerhardus and Razum have recently noted that the “...unwarranted confidence in the new [HPV] vaccines led to the impression that there was no need to actually evaluate their effectiveness” [11].

Similarly, the notion that HPV vaccines have an impressive safety profile can only be supported by highly flawed design of safety trials [2,13] and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities) [2,4,14]. For example, compared to all other vaccines in the U.S. vaccination schedule, Gardasil alone is associated with 61% of all serious adverse reactions (including 63.8% of all deaths and 81.2% cases of permanent disability) in females younger than 30 years of age [12].

Although a report to a vaccine safety surveillance system does not by itself prove that the vaccine caused an adverse reaction, the unusually high frequency of adverse reactions related

to HPV vaccines reported worldwide, as well as their consistent pattern (i.e. nervous system- related disorders rank the highest in frequency), points to a potentially causal relationship [2]. Furthermore, matching the data from vaccine surveillance databases is an increasing number of case reports documenting similar serious adverse reactions associated with HPV vaccine administration, with nervous system and autoimmune disorders being the most frequently reported in the medical literature [15-24].

In summary, the optimistic claims that HPV vaccines will prevent cervical cancers and save lives, and that they are extremely safe, rest on assumptions which are misinterpreted and presented to the public as factual evidence. We thus conclude that further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no serious health risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles [2,25].

To those who wish to promote HPV vaccination as a means for reducing cervical cancer burden, perhaps the following should be asked:

1. HPV vaccines have not been demonstrated to prevent any cervical cancers so why are they being promoted as cervical cancer vaccines?

2. If the majority of HPV infections and a great proportion of pre-cancerous lesions clear spontaneously and without medical treatment and are thus not a reliable indication of cancer later in life, then how can these end-points be used as a reliable indicator of the number of cervical cancer cases that will be prevented by HPV vaccines?

3. How can the clinical trials make an accurate estimate of the risk associated with HPV- vaccines if they are methodologically biased to produce type-2 errors (false negatives [2,4,13])?

4. Can a passive monitoring system such as that used by most vaccine surveillance systems world-wide allow the medical regulatory agencies to make accurate estimates on the real frequency of HPV-vaccine related adverse reactions?

5. Can an accurate estimate of the real frequency of HPV-vaccine related adverse reactions be made if appropriate follow-up and thorough investigation of suspected vaccine related ADRs is not conducted but instead, these cases are a-priori dismissed as being unrelated to the vaccine?

6. Why are women not informed of the fact that in some circumstances (i.e., prior exposure to vaccine-targeted and non-targeted HPV types), HPV vaccination may accelerate the progression of cervical abnormalities [4,26-28]?

7. How can women make a fully informed decision about whether or not to consent to vaccination if crucial information regarding HPV vaccine efficacy and safety is not being disclosed to them?

8. Should the medical health regulators and authorities rely solely on data provided by the vaccine manufacturers to make vaccine-policy decisions and recommendations [12,29]?

Competing interests

The authors declare that they have no conflict of interests.

Authors’ contributions

LT was involved in choosing the topic and drafting the initial manuscript. CAS, JW, EV and TB were involved in critically revising the manuscript and additional content. The authors have read and approved the manuscript. This work was supported by the Dwoskin and Katlyn Fox Family Foundations.


1. de Sanjose S: HPV prevention series. Infect Agent Cancer 2012, 7(1):37.

2. Tomljenovic L, Shaw CA, Spinosa JP: Human Papillomavirus (HPV) Vaccines as an option for preventing cervical malignancies: (How) effective and safe? Curr Pharm Des 2012, :CPD-EPUB-20120924-13. Epub ahead of print.

3. Tomljenovic L, Shaw CA: Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety? Am J Public Health 2012, 102(9):e13–e14.

4. Tomljenovic L, Shaw CA: Human papillomavirus (HPV) vaccine policy and evidence- based medicine: are they at odds? Ann Med 2011, doi:10.3109/07853890.2011.645353.

5. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010, 116(6):1373–1380.

6. Castle PE, Schiffman M, Wheeler CM, Solomon D: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113(1):18–25.

7. Castle PE, Stoler MH, Solomon D, Schiffman M: The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007, 127(5):805–815.

8. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE: Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2009, 171(2):155–163.

9. Carreon JD, Sherman ME, Guillén D, Solomon D, Herrero R, Jerónimo J, Wacholder S, Rodríguez AC, Morales J, Hutchinson M, et al: CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of populationbased cervical samples. Int J Gynecol Pathol 2007, 26(4):441–446.

10. Schiffman M, Rodriguez AC: Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008, 9(5):404–406.

11. Gerhardus A, Razum O: A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health 2010, 64(5):377–378.

12. Tomljenovic L, Shaw CA: Too fast or not too fast: the FDA’s approval of Merck’s HPV vaccine gardasil. J Law Med Ethics 2012, 40(3):673–681.

13. Tomljenovic L, Shaw CA: No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? J Intern Med 2012, 272(5):514–515.

14. Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, Qureshi AI: Guillain-Barre syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006–2009. Vaccine 2011, 29(5):886–889.

15. Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfiel ML, Muniz Montes JR:

Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia 2010, 25(1):58–59.

16. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C: Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009, 72(24):2132–2133.

17. DiMario FJ Jr, Hajjar M, Ciesielski T: A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010, 25(3):321–327.

18. Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G: Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine 2009, 27(28):3690.

19. Melo Gomes S, Glover M, Malone M, Brogan P: Vasculitis following HPV immunization. Rheumatology (Oxford) 2012, :2012. doi:10.1093/rheumatology/kes168.

20. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R: Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2011, 82(11):1296–1298.

21. McCarthy JE, Filiano J: Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 2009, 15(10):792–794.

22. Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V: Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011, 29(29– 30):4654–4656.

23. Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH: CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009, 15(1):116–119.

24. Tomljenovic L, Shaw AC: Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental? Pharm Reg Affairs 2012, S12:001. doi:104172/2167- 7689S12-001.

25. Tomljenovic L, Shaw CA: Mandatory HPV vaccination. JAMA 2012, 307(3):254. author reply 254–255.

26. Spinosa JP, Riva C, Biollaz J: Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in press. Cancer Lett 2011, 304(1):70.

27. U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC): VRBPAC Background Document: GardasilTM HPV Quadrivalent Vaccine. May 18, 2006 VRBPAC Meeting. [http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf].

28. Beller U, Abu-Rustum NR: Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009, 113(2 Pt 2):550–552.

29. Mello MM, Abiola S, Colgrove J: Pharmaceutical companies’ role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 2012, 102(5):893–898.

jackie@jabs.org.uk © John Fletcher 2012